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Heart failure
●
●
●

~6.2 million adults in the US
High costs: $30.7 billion (‘12)
Treatment guidelines HFrEF
(2017):
Beta blocker + diuretic +
ACEi/ARB/ARNI

SGLT-2 inhibitors
●
●
●

Block glucose reabsorption
in blood
Increased urinary glucose &
sodium secretion
Side effects:
○
○
○
○
○
○

Increased UTI
Genital mycotic infections
Increased risk of DKA
Fournier’s gangrene
AKI
Hypotension, dehydration

SGLT-2 inhibitors
“Gliﬂozins”:
●
●
●
●

Canagliﬂozin (Invokana)
Dapagliﬂozin (Farxiga)
Empagliﬂozin (Jardiance)
Ertugliﬂozin (Steglatro)

Previous evidence
●

●
●
●

SGLT2 inhibitors decrease risk of ﬁrst
hospitalization for heart failure in patients
with DM2 (25 - 35%) = prevention
CANVAS + EMPA-REG: mechanisms CV
beneﬁt likely driven by reduced HF death
EMPA-REG OUTCOME: reduced risk of
pump failure and sudden deaths
DECLARE-TIMI 58: no reduction in major
adverse CV events, but reduction in CV
death or HF hospitalization (Esp. HFrEF)

→ Can SGLT-2 inhibitors treat HFrEF?

Previous evidence
●

Beneﬁts on HF could not be explained by
diuretic or anti-hyperglycemic effects

●

Beneﬁts may be mediated by the
inhibition of sodium-hydrogen exchange
rather than the effect on glucose
reabsorption
Reduced cardiac injury, hypertrophy,
ﬁbrosis, systolic dysfunction

●

→ Will it work for patients without DM?

Aim
“To prospectively evaluate the efﬁcacy and safety of the SGLT2 inhibitor
dapagliﬂozin in patients with heart failure and a reduced ejection fraction,
regardless of the presence or absence of diabetes”

● Trial design

Methods

● Patients
● Outcomes
● Statistical analyses

Methods - Trial design
●
●

Phase 3, Randomized, Double-Blinded
Placebo-controlled
○
○

●
●
●
●

410 centers in 20 countries
N = 4744
Stratiﬁcation: DM2 (A1c ≥ 6.5%)
Median follow up time: 18.2 months
○

●

Dapagliﬂozin 10 mg vs Placebo
+ Conventional HF therapy

14 days, 60 days, q4 months

In collaboration with sponsor: AstraZeneca
○

Analyses replicated by independent academic group

Clinical Trials

Methods - Patients
Inclusion criteria:
●
●
●
●

●

Age ≥ 18 years
EF ≤ 40%
NYHA class II-IV
NT-proBNP ≥ 600 pg/ml
○

or ≥ 400 pg/ml if HF hospitalization in previous 12 mo)

○

Aﬁb or Aﬂutter: NT-proBNP ≥ 900 mg/ml

Standard treatment for heart failure
○
○

●

Device: ICD, cardiac resynchronization therapy, or both
Meds: ACEi, ARB, sacubitril-valsartan + beta-blocker +/- mineralocorticoid receptor antagonist

DM: continued to take glucose-lowering therapy
○

Doses could be adjusted as required (insulin, sulfonylurea)

Methods - Patients
Exclusion criteria:
●
●
●
●
●

Recent treatment with SGLT2 inhibitor
Unacceptable side effects associated with SGLT2 inhibitor
DM type 1
Symptomatic hypotension or SBP < 95 mmHg
eGFR ≤ 30

Methods - Outcomes
Primary outcome:
●

Composite of worsening heart failure or death from cardiovascular causes
○ Hospitalization
○ Urgent visit resulting in IV therapy for HF

Methods - Outcomes
Secondary outcomes:
●
●
●
●
●

Composite of hospitalization for heart failure or cardiovascular death
Total number of hospitalizations for HF & cardiovascular deaths
Change in symptoms
○ Kansas City Cardiomyopathy Questionnaire
Composite of worsening renal function
○ ≥ 50% decline in eGFR, ESRD (eGFR≤ 15 for ≥ 28 days) , renal death
Death from any cause

Methods - Outcomes
Safety analysis:
●
●
●

Serious adverse events
Adverse events associated with discontinuation of a trial treatment
Adverse events of interest
○
○
○
○
○
○
○

●

Volume depletion
Renal events
Major hypoglycemic events
Bone fractures
DKA
Amputations
Fournier’s gangrene

Abnormal lab ﬁndings of note

*Data on other adverse events not routinely collected given
extensive previous collection on safety data regarding dapagliﬂozin
(Wiviott ea 2019)

Methods - Statistical Analysis
●
●
●

Intention-to-treat analysis
Time-to-event data: Kaplan-Meier estimates & cox proportional-hazards
models
Incidence of adverse events: Fisher’s exact test

Cox proportional hazards model
Relate several risk factors/exposures, considered simultaneously, to survival time
Effect measured: Hazard rate = Probability of an individual at time t has event
happening at that time
Hazard Ratio = Probability of events in treatment group / probability of events in
control group
Averaged over the whole follow-up period
HR ≠RR
→ Time to event

Results

● Efﬁcacy Outcomes
● Safety Outcomes

Primary outcome - Worsening HF or CV death
HR 0.74
Dapa → 26% less risk of
developing worsening HF
or CV death, at any time
NNT = 21

Secondary outcome - HF hospitalization

Secondary outcome - mortality

Efficacy outcomes

Effect by subgroups

Primary outcome - subgroup analysis

Effect by subgroups

Subgroup analysis - DM vs no DM
Patients without DM2 (n=2605)

Patients with DM2 (n-2139)

Discussion

● Summary of ﬁndings
● Strengths
● Limitations

Discussion
●

●
●

When added to standard therapy, dapagliﬂozin reduced the risk of worsening
HF events and CV death, and improved symptoms in patients with HFrEF, both
with and without DM
Beneﬁts occurred early after randomization
Dapagliﬂozin was well tolerated
○

●

<8% volume depletion or worsening kidney function

Rate of treatment discontinuation due to adverse event was low (<5%)

→ Dapagliﬂozin offers new approach to treatment of HFrEF in
patients with and without DM

& Appears to be safe

Discussion - Strengths
●
●
●

●
●

RCT
Large patient population
Multicenter trial across different
countries
○ Increased external validity
Independent analyses from
sponsor
Follow up time 24 months

Discussion - Limitations
●

●
●

Limited generalizability due to
speciﬁc inclusion and exclusion
criteria
<5% black patients
Few very elderly patients with
multiple coexisting illnesses

●
●
●
●

Few NYHA III or IV
Women ~ 25%
Mean BMI ~ 28
Not included in AE: UTI’s, yeast infx

Mechanism of action?
Hypotheses:
●
●
●
●

SGLT2 inhibitors mitigate glycemia-related cardiotoxicity
Enhanced ketogenesis contributes to the beneﬁt of heart failure
Renal sodium excretion
Increase in hematocrit favorable for CAD
○

Increase in hematocrit did not affect clinical course of pts with HF

DAPA-HF did not support the above hypotheses

FDA approval
●
●

May 5 2020
Dapagliﬂozin approved speciﬁcally for the treatment of patients with heart
failure and a reduced ejection fraction

New Guidelines

Future directions
●

EMPEROR-Reduced trial (NEJM,Aug 2020): empagliﬂozin, more severe HF
○

●
●
●

Similar results

RCT dapagliﬂozin vs empagliﬂozin
Most effective dosage
Mechanism of action

Practice implications for JFMA
●
●

Dapagliﬂozin 10mg seems to be effective & safe for patients with mild-mod
HFrEF in reducing worsening HF and death
Additional data needed
○
○
○
○

●
●

More severe HF
More diverse patient population
Higher BMI
More comorbidities

How to explain to our patients?
High costs
○

Discount not for Medicare/Medicaid
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Questions?

Methods - Procedures
●
●

14 day screening period: baseline criteria, in- and exclusion criteria
Random assignment to treatment vs placebo group
○

●
●

Dapagliﬂozin 10mg once daily

Randomization: sequestered, ﬁxed-randomization schedule; use of balanced
blocks → 1:1 ratio

Methods - Procedures

-

Assessment of heart failure &
volume status, adverse events,
evaluation of renal function and
potassium levels.

Reassess

Reassess

14 days

4 months

12 months

60 days

8 months

Assessment of heart failure &
volume status, adverse events,
evaluation of renal function and
potassium levels.

Reassess

16- 24 months

Reassess

Dapagliﬂozin or placebo discontinued if pregnancy, DKA
Dose reduction or temporary discontinuation: if acute unexpected decline in eGFR, volume depletion or
hypotension

MOA

Time to event
Hazard = instantaneous event rate
Probability of an individual at time t has event happening at that time
Hazard Ratio
Probability of events in treatment group / probability of events in control group
●
●

HR =1 (at any time, event rates similar in both arms)
HR 0.5 (at any time, half as many patients in treatment group are having an
event proportionally to comparison group )

HR ≠RR

Relative Risk (Risk Ratio) =
Risk (cumulative incidence) treatment group / risk placebo group
Relative Risk Reduction (efﬁcacy) = 1-RR
Relative decrease in risk of event in exposed group compared to unexposed group
Absolute Risk Reduction
Disease risk in placebo group - disease risk in treatment group
NNT = 1/ARR
How many patients need treatment before 1 patient beneﬁts

